



Strategic Partner Management

TruPoints is the first business development invention constructed expressly to help life science industry companies license or raise money for clinical stage product candidates.

Think of TruPoints as the scientist's marketing tool — the best way to package trial data for monetization success.



CLINICAL TRIAL SPONSORS

Easily share study documents with licensing partners, potential partners, and investors

INVESTORS

Keep up to date with the status of their portfolio companies, without additional reporting burden

INVESTMENT BANKS

Greatly improve deal flow and the management of the entire due diligence process.

COMMERCIAL PARTNERS

Meets their particular needs in the review and evaluation process

Key Features


- Extremely intuitive user interface fully dedicated to the needs of life sciences companies
- Display of live or time delayed clinical study metrics via live connection to popular clinical data management systems
- Full featured customizable web page presentation tool with the ability to highlight your assets with graphics, video and more
- Easy to use document framework that maps all key documents applicable for regulatory submission to an eCTD format
- No downloads required, no installation of any software, no ActiveX™ or Java™
- Project management access available through smart phones and tablets such as iPhone and iPad

Benefits

- Accelerates deals
- Gives a complete picture of your trial
- Framework for eCTD submission
- Ideal for competitive bidding process
- Eliminates administration burden and cost
- Monitoring use with advanced audit trail
- Better relationship management
- Secure and easy to use

Support

Both user and project management support provided through our 24x7x365 help desk (with automated support for user ID, password and user preferences). You will also have access to experienced life sciences experts – we have managed trials, managed biotechs, and directly facilitated numerous financings and transactions. We understand the business you are in from beginning to end. And our easy to use document framework maps all key documents applicable for regulatory submission to an eCTD format.



TruPoints® Designer Console - Document Manager

Designer Name: Jack Houriet (Administrator) TruPoints® Designer - Document Manager Pharmacoglobal - 1000

Users Document Manager Companies Content Category Default Document Map eCTD Map Videos/Static Charts Reports

Hide Inactive Documents

Pharmacoglobal/Business Information/Intellectual Property/

Filename	LastUpdateUser	LastUpdate	Active
US Patent 7,657,446.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 6,298,347.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 7,788,114.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 6,834,285.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 7,496,610.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 7,233,960.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active
US Patent 7,636,668.pdf	Jack Houriet	2/18/2011 9:53:43 AM	Active

Business Information - Intellectual Property

Documents that you have already reviewed are indicated by ✓. Windows Media Player (version 10.0 or higher) is required files.

- ✓ US Patent 7,657,446.pdf (PDF) Last viewed at 5/16/2011 12:13:43 PM
US Patent 7,657,446 AUTOMATED IDENTIFICATION OF TASKS THAT MUST BE COMPLETED BEFORE A CLINICAL TRIAL DATABASE CAN
- ✓ US Patent 6,298,347.pdf (PDF) Last viewed at 4/21/2011 12:46:30 PM
US Patent 6,298,347 SYSTEM AND ENTRY METHOD FOR REMOTE DATA ENTRY
- ✓ US Patent 7,788,114.pdf (PDF) Last viewed at 2/18/2011 9:30:13 AM
US Patent 7,788,114 METHOD AND ARTICLE OF MANUFACTURE OF PERFORMING CLINICAL TRIAL BUDGET ANALYSIS
- ✓ US Patent 6,834,285.pdf (PDF) Last viewed at 2/18/2011 9:54:25 AM
US Patent 6,834,285 COMPUTER SYSTEM FOR PORTABLE DIGITAL DATA CAPTURE AND DISTRIBUTION
- ✓ US Patent 7,496,610.pdf (PDF) Last viewed at 2/18/2011 9:54:31 AM
US Patent 7,496,610 COMPUTER SYSTEM FOR PORTABLE DIGITAL DATA CAPTURE AND DISTRIBUTION
- ✓ US Patent 7,233,960.pdf (PDF) Last viewed at 2/18/2011 9:54:36 AM
US Patent 7,233,960 SYSTEM AND METHOD FOR MOBILE WIRELESS ELECTRONIC DATA CAPTURE AND DISTRIBUTION OF A MERCHANDISE PROCESSING APPL
- ✓ US Patent 7,636,668.pdf (PDF) Last viewed at 2/18/2011 9:54:40 AM

Pharmacoglobal Inc.

Pretenda® (PHG-509) - Mickleton's Disease. Our most advanced product candidate is Pretenda, a topical formulation which uses FOO to deliver 0.9% hemipuffin, a proven vasodilator, for the prevention and treatment of Mickleton's with a side effect profile distinctly different from other hemipuffin formulations (headaches and dizziness not different from arthra-va-hal). Mickleton's episodes or attacks are typically triggered by exposure to light and an episode can last up to two hours. Since there are no currently approved drug treatments for Mickleton's, physicians utilize existing medications off label, such as calcium channel blockers, to try to control the symptoms of Mickleton's often without acceptable outcomes in the view of the patients.

According to recent market research commissioned by us, there are greater than 2 million diagnosed patients in the United States seeking medical treatment for Mickleton's. Patients with Mickleton's seek treatment mainly from rheumatologists and primary care physicians ("PCPs"). Epidemiology studies estimate there are at least an additional nine million patients with Mickleton's in the U.S., with corresponding Mickleton's patient populations in Europe and Asia. Pharmacoglobal submitted an NDA for Pretenda in April 2008 and received notice in June 2009 that it was accepted for filing. Pretenda received priority review. Following a Complete Response letter from the FDA in October 2009, the Company met with the agency and worked out a protocol for an additional study (now underway), to complete the NDA requirements.

Contact Information:
Terrance McGovern
Managing Director
215-238-8881

Charts

Executive Summary Site Completion Study Status

Number of Subjects

Weeks of Study (11/09/2009 To 06/25/2010)

Click on chart to enlarge

Recent Updates

- Pharmacoglobal prepares launch of 09-002 Study
- Spain site visited
- First patient randomized at Dr. Martin's site
- Sehaleth site visited
- First patient screened at Dr. Martin's site